Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | PNLIP | P16233 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | TPO | P07202 | 1/20 | 0.39 |
| ▸ | EPX | P11678 | 1/20 | 0.39 |
| ▸ | LPO | P22079 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484062 | 0.89 | ERBB2 (0.46) | SCN9ACCNCCDK8CDK19ERBB2 | |
| SCHEMBL3485177 | 0.85 | ACACB (0.43) | ACACBPNLIPCNR2GRM4CDK8 | |
| SCHEMBL3510341 | 0.84 | EPHX2 (0.51) | PNLIPERBB2EPHX2NR1H4 | |
| SCHEMBL3484654 | 0.83 | MEN1 (0.53) | — | |
| SCHEMBL3483897 | 0.75 | ERBB2 (0.42) | SCN9AERBB2 | |
| SCHEMBL3484041 | 0.75 | EGFR (0.68) | ERBB2 | |
| SCHEMBL3484176 | 0.74 | EGLN1 (0.38) | ACACBCNR2GRM4 | |
| SCHEMBL3507398 | 0.74 | MRGPRX4 (0.46) | ERBB2EPHX2NR1H4 | |
| SCHEMBL27576048 | 0.73 | RAF1 (0.51) | ACACBPNLIPGRM4 | |
| SCHEMBL159190 | 0.72 | MPO (0.51) | PNLIPGRM4MPOTPOEPX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | ACACB 2574/4885SCN9A 3444/4885PNLIP 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.